Introduction
Acute myeloid leukemia (AML) frequently occurs in older patients, with a poor prognosis due to more resistant disease and increased patient frailty. 1 Patients likely to benefit from intensive chemotherapy combining standard doses of cytarabine arabinoside (AraC) with an anthracycline ("7+3" regimen) can be identified by various scores, 2-4 including a proposed decision index (DI) derived by our group. 5 Age, cytogenetics, white blood cell count (WBC), antecedent hematological disorders (AHD), performance status (PS), and comorbidities are the main factors which are taken in consideration for decision-making. In selected patients, standard intensive induction yield complete remission (CR) rates around 50%. 6 Induction dose escalation does not improve outcome after 65 years of age. 7 Once CR has been reached, there is no well-established standard for post-remission therapy in older AML patients. Randomized studies from the 1990s failed to demonstrate any benefit of intensification either by increasing the doses, 8 number of courses, 9 or number of chemotherapy agents, 10 except in highly selected patients. 10 Since the conduction of those studies, the prognosis of older AML patients treated intensively might have improved with progresses in supportive care, 11 warranting a reappraisal of the potential benefit associated with intensive post-remission therapy.
The Acute Leukemia French Association (ALFA) completed a trial in AML patients aged over 65 years with de novo or secondary AML (ALFA-9803) 12 that randomized patients in first CR between two post-remission strategies, an intensive regimen delivered in the hospital, and an ambulatory strategy consisting of six courses of single-dose anthracycline combined to subcutaneous AraC. Though this study was the first to demonstrate an overall survival advantage in favor of the ambulatory approach, this conclusion was hampered by the fact that the "intensive" arm consisted of a single "3+7" reinduction course, leaving the possibility that a more intensive post-remission strategy could have been more efficient, especially in younger patients close to 65 years of age. Concomitantly, the ALFA initiated another trial, referred to as ALFA-9801 and designed for patients aged 50 to 70 with de novo AML. 13 In this trial, patients in CR received a more intensive post-remission regimen with two courses of intermediate-dose
AraC, combined to anthracyclins. 13 The 65-70 years age overlap in these two concomitant trials 4 inclusion criteria provided the opportunity to compare different intensities of post-remission treatment in older patients with de novo AML in first CR.
Design and Methods

Patients and eligibility criteria
The de novo AML were analyzed in the present study. The CONSORT diagram of the study population is recapitulated in Figure 1 .
Treatments
Both trial treatment schemes are summarized in Figure 2 and detailed in references 12 and 13.
In both trials, patients were randomized front-line (first randomization: R1) to receive either 
Decision Index
The Decision Index (DI) was defined according to ref. 5 . As the age criterion ≥75 years taken in consideration by this DI was not relevant to the present cohort, only PS and WBC criteria were used to define patients with unfavorable index. Briefly, an unfavorable index was assigned to patients with high-risk cytogenetics and/or the two following factors: PS ≥2 and WBC ≥50 G/L, or a favorable index in the absence of these criteria.
Response criteria
Responses were classified according International Working Group criteria. 14 Induction death was defined as death occurring before response evaluation unless evidence of resistant disease (defined according to ref. 14) was provided at least 7 days after conclusion of the chemotherapy.
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Cytogenetics
Cytogenetic abnormalities were evaluated according to ISCN criteria; 15 with at least 15 normal mitoses to define a cytogenetically normal AML (CN-AML); t(8;21), inv(16) or t(16;16) were considered as favorable risk. According to ALFA cytogenetic classification, the unfavorable-risk subset included del(5q)/-5, del(7q)/-7, 11q23 anomaly (except for t(9;11)), t(6;9), complex karyotype (≥ 3 abnormalities), and 3q26 abnormalities. All other aberrations as well as normal karyotypes were included in the intermediate-risk subset.
Endpoints and statistical methods
The primary endpoints were overall survival (OS) and OS from CR, using first day of induction therapy or date of complete remission as landmark, respectively. Patients were censored at the date of last contact if alive. Survival life-tables were estimated with the Kaplan-Meier method, 16 with median follow-up determined according to Korn et al. 17 Secondary endpoints were diseasefree survival (DFS) measured from CR date considering death and relapse as events, and postremission treatment related mortality (TRM), measured as the cumulative incidence of death in first CR at one year of treatment onset, considering relapse as a competing risk. All analyses were stratified on front-line anthracycline randomization, regrouping the two 9801 IDA arms to form only two groups in total (DNR and IDA). For that purpose, bivariate logistic regression was used for dichotomic variables, and stratified log-rank tests for survival analysis. All tests were two-sided with an alpha value of 0.05. All analyses were carried on the Statview (SAS, Cary, NC, USA) and R 2.10.1 softwares.
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Results
Patients characteristics
A total of 211 patients with de novo AML and aged 65 to 70 were identified as the overlap population, 76 patients from the ALFA-9801 trial and 135 from the ALFA-9803 trial (Figure 1 ). One hundred and twenty-three of those patients reached CR after one cycle. Fourteen (50%) and 21 (35%) of the 28 and 60 patients resistant to the first induction cycle in the 9801 and 9803 trials respectively received salvage therapy. Respectively 5 and 2 of those patients achieved CR after salvage. Eighty-one patients failed to reach CR because of induction death in 12 (5%) and resistant disease in 69 (33%). There was no difference in CR, CR after one course, ID, or RD rates between both trial subgroups ( Table 2) .
Impact of trial on overall survival
The median follow-up of the 211 patients was 34 months. In univariate analysis, only karyotype impacted OS (hazard ratio=1. Figure 3C ). Figure 4A ). In univariate analysis, cytogenetics, age, or WBC, had no significant impact on OS from CR ( 
Discussion
There is no validated standard post-remission therapy for older AML patients once they have reached CR after intensive induction chemotherapy. In previous randomized trials, the outcome of CR patients was similar whatever the intensity of post-remission treatment. that there is no apparent benefit to intensify the post-remission treatment in this age range, using either one or two intensive consolidation courses.
In this comparison, patient and disease characteristics were comparable in the two trial subgroups, except for a statistically significant 1-year median age difference probably of no clinical relevance in the age interval considered. The rate of patients receiving IDA was higher in the 9801 trial, but, though there was a benefit in CR rates in favor of idarubicin arms in trial 9801, 21 anthracyclines had no effect on OS or DFS in the two trials. 12, 21 In addition, all analyses were stratified on the anthracyclin drug used for each patient. As both trials were run concurrently in most sites, some bias may have been present, with patients with poorer status being preferentially accrued to the less intensive 9803 trial. However, patients had comparable WBC, cytogenetics and performance status in the two trials (Table 1 ; all p>0.20). Furthermore, such a potential bias should have favored the more intensive 9801 trial, when our results show that outcomes were strictly superposable in the two trials.
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A recent European study has shown that intensified anthracycline doses during induction may benefit to older AML patients, but only until 65 years of age. 7 Though carried on a limited number of patients, the present study failed to demonstrate any substantial benefit for intensifying the post-remission chemotherapy with two courses of intermediate-dose AraC, maybe due to a higher treatment-related mortality as compared to less intensive approaches.
Conversely, we did not observe a significant benefit of ambulatory over intensive courses as seen in the global 9803 cohort 12 . This may be due to the smaller number of patients analyzed here, or to the selection of patients with overall better-risk cytogenetics due to exclusion of secondary AML cases. In younger patients, Nucleophosmin1 (NPM1)-mutated AML without fms-like tyrosine kinase 3 (FLT3) internal tandem duplication (FLT3-ITD), that often carry a normal karyotype 22 , share a favorable prognosis with CBF-AML after chemotherapy alone 23 .
NPM1 mutations also have a favorable prognostic impact in older AML patients. 24 Molecular data was not available in our patient cohorts. However, the relatively small number of patients with CBF-AML or CN-AML leukemia as a whole did not seem to benefit from the intensification of post-remission treatments, the CBF-AML subgroup being too small to be individualized in this study. Restricting our analyses to CN-AML only did not affect these conclusions.
Even though restricted to patients under 70 years and including a majority of intermediate-risk cytogenetics, our study population included patients not likely to benefit from intensive therapy according to the decision index our group has proposed, 5 and should instead be candidates to investigational therapies. Restricting our analysis to patients with a favorable decision index, mostly by exclusing of patients with high-risk cytogenetics, there was still no benefit for a more intensive strategy neither in terms of global strategy, nor of post-remission therapy, as assessed by OS and OS from CR respectively.
Aside from overall lower dose intensity in trial 9803 compared to 9801, a number of differences between those two trials may have affected patient outcome. G-CSF, used only during the induction and reinduction courses of the 9803, has only been shown to improve CR rates in some studies. 25 A second difference between the three different post-remission schemes was the higher cumulative dose of anthracycline delivered in the less intensive 9803 ambulatory arm (Figure 2 ). It maybe that increasing the cumulative dose of anthracycline e 13 prolongs remission duration, as suggested by the increased remission rate oberved in older AML with use of doubled dose of daunorubicin during induction. 7 Conversely, it is unlikely that the IL-2 maintenance of trial 9801 could have impacted outcome, as only 17 patients were randomized to receive maintenance, and interleukin-2 was not found to affect survival in several studies including our 9801 trial. 13, 26 Overall, our findings suggest that in older patients with AML in complete remission, there is no apparent benefit to use an intensified post-remission treatment scheme derived from younger adult AML protocols. Whether this may also hold in the selected subgroups of patients with normal karyotype and favorable genotypes or with favorable karyotype remains to be determined. In a large retrospective analysis of older patients with CBF-AML, use of intermediate cytarabine, compared to less intensive consolidations appeared of possible survival benefit at least in those carrying an AML1/ETO fusion gene. 27 Finally, the overall disappointing results of current intensive strategies in older AML patients should prompt investigation of alternative post-remission treatments in the majority of these patients, using novel agents and/or novel allogeneic stem cell transplantation procedures, rather than modulating dose intensity of conventional chemotherapy. A. OS from CR in all CR patients (n=130).
B. OS from CR in CBF or CN-AML patients (n=67).
C. OS from CR in patients starting planned post-remission Tx (n=103).
